<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Espoguia (clinical guidelines for patients with spondyloarthritis).&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Espoguia Group. Espoguia. Clinical guidelines for patients with spondyloarthritis. Madrid: Spanish Society of Rheumatology; 2010. 289 p.  [1104 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is planned to update ESPOGUIA about every 2 years.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Ankylosing spondylitis  (720.0); General physical examination  (89.7); Occupational therapy  (93.83); Psoriatic arthropathy  (696.0); Regional enteritis of unspecified site  (555.9); Synovectomy, unspecified site  (80.70); Ulcerative colitis, unspecified  (556.9); Unspecified disorder of intestine  (569.9)"/><FieldValue Value="MSH: Analgesics ; Anti-Inflammatory Agents, Non-Steroidal ; Antibodies, Antinuclear ; Antirheumatic Agents ; Arthritis, Psoriatic ; Arthritis, Reactive ; Balneology ; Blood Cell Count ; Blood Sedimentation ; C-Reactive Protein ; Colitis, Ulcerative ; Comorbidity ; Crohn Disease ; Diphosphonates ; Exercise ; Fluorescent Antibody Technique ; Glucocorticoids ; HLA-B27 Antigen ; Hyperthermia, Induced ; Inflammation ; Inflammatory Bowel Diseases ; Injections, Intra-Articular ; Intestinal Diseases ; Kidney Function Tests ; Life Style ; Liver Function Tests ; Massage ; Medical History Taking ; Musculoskeletal Manipulations ; Occupational Therapy ; Orthopedic Equipment ; Orthopedic Procedures ; Pain ; Pain Management ; Patient Education as Topic ; Physical Examination ; Physical Therapy Modalities ; Psoriasis ; Radiography ; Referral and Consultation ; Rehabilitation ; Rheumatoid Factor ; Spondylarthritis ; Spondylitis, Ankylosing ; Thalidomide ; Transcutaneous Electric Nerve Stimulation ; Urinalysis ; Uveitis "/><FieldValue Value="MTH: Analgesics ; Ankylosing spondylitis ; Anti-Inflammatory Agents, Non-Steroidal ; Antibodies, Antinuclear ; Antirheumatic Agents ; Arthritis, Reactive ; Balneology ; blood cell count ; Blood Sedimentation ; C-reactive protein ; C-reactive protein measurement ; Calcium measurement ; Crohn Disease ; Diphosphonates ; Exercise ; Fluorescent Antibody Technique ; Glucocorticoids ; HLA-B27 Antigen ; Induced Hyperthermia ; Inflammation ; Inflammatory Bowel Diseases ; Intestinal Diseases ; Intra-Articular Injections ; Kidney Function Tests ; Life Style ; Liver Function Tests ; Massage ; Occupational therapy regime ; Pain ; Pain management ; Patient education (procedure) ; physical examination ; Physical function test ; Physical therapy ; Radiographic imaging procedure ; Regional enteritis ; Rehabilitation therapy ; Rheumatoid Factor ; Rheumatoid Factor Measurement ; Spondylarthritis ; Synovectomy ; Transcutaneous Electric Nerve Stimulation ; Ulcerative Colitis ; urinalysis ; Uveitis "/><FieldValue Value="PDQ: fluorescent antibody technique ; pain ; pain therapy ; physiotherapy ; thalidomide "/><FieldValue Value="SNOMEDCT_US: Analgesic  (373265006); Analgesic  (53009005); Ankylosing spondylitis  (9631008); Anti-rheumatic agent  (372888006); Anti-rheumatic agent  (88279005); Anti-tumor necrosis factor alpha drug  (416897008); Anti-tumor necrosis factor alpha drug  (420693002); Antinuclear antibody  (45530001); Arthritis of spine  (371082009); Blood cell count  (88308000); C reactive protein  (61425002); C-reactive protein measurement  (55235003); Calcium measurement  (71878006); Crohn's disease  (34000006); Diphosphonate  (372907000); Diphosphonate  (96281001); Disorder of intestine  (85919009); Erythrocyte sedimentation  (416560009); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fluorescent identification of anti-nuclear antibody  (5733007); Glucocorticoid  (116596006); Glucocorticoid  (35150008); Glucocorticoid  (419933005); HLA B27 antigen screening test  (314096001); HLA-B27 antigen  (34453005); Inflammation  (23583003); Inflammation  (257552002); Inflammatory bowel disease  (24526004); Intra-articular injection  (27813003); Juvenile ankylosing spondylitis  (239805001); Life style  (134436002); Life style  (60134006); Liver function tests - general  (26958001); Liver function tests - general  (271552009); Musculoskeletal system physical examination  (363215001); Non-steroidal anti-inflammatory agent  (16403005); Non-steroidal anti-inflammatory agent  (372665008); Occupational therapy  (84478008); Orthopedic aid  (16349000); Orthopedic aid  (309858006); Pain  (22253000); Pain management  (278414003); Patient education  (311401005); Periarticular injection  (182640003); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Physical therapy procedure  (91251008); Post-bacterial arthropathy  (129133005); Post-bacterial arthropathy  (239783001); Psoriasis  (9014002); Psoriasis with arthropathy  (33339001); Radiographic imaging procedure  (363680008); Referral to rheumatologist  (306290009); Rehabilitation therapy  (52052004); Renal function study  (44277000); Rheumatoid factor  (77089006); Rheumatoid factor measurement  (54921001); Synovectomy  (388990007); Thalidomide  (404878004); Thalidomide  (78702007); Thermotherapy  (261570006); Transcutaneous electrical nerve stimulation  (229559001); Transcutaneous electrical nerve stimulation  (432061000124105); Ulcerative colitis  (64766004); Urinalysis  (167217005); Urinalysis  (27171005); Urine concentration test  (13956007); Urine concentration test  (63840000); Uveitis  (128473001)"/><FieldValue Value="SPN: SYSTEM, TEST, C-REACTIVE PROTEIN "/><FieldValue Value="UMD: Radiographic Systems  (18-429)"/></Field></Section><Section SecID="394" OrdBy="200" Name="Regulatory Alert"><Field FieldID="154" OrdBy="205" ID="395" Name="FDA Warning/Regulatory Alert" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse&lt;/strong&gt;: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;a href=&quot;http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm454141.htm&quot; title=&quot;FDA Web site&quot; target=&quot;_blank&quot;&gt;July 9, 2015 - Non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDS)&lt;/a&gt;: The U.S. Food and Drug Administration (FDA) is strengthening an existing label warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) increase the chance of a heart attack or stroke. Based on FDA&amp;rsquo;s comprehensive review of new safety information, FDA is requiring updates to the drug labels of all prescription NSAIDs. As is the case with current prescription NSAID labels, the Drug Facts labels of over-the-counter (OTC) non-aspirin NSAIDs already contain information on heart attack and stroke risk. FDA will also request updates to the OTC non-aspirin NSAID Drug Facts labels. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Spondyloarthritis (SpA), including:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ankylosing spondylitis (AS) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reactive arthritis (ReA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Arthritis-related inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psoriatic arthritis (PsA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Undifferentiated SpA (uSpA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Juvenile-onset AS (JoAS) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The terms &quot;spondyloarthropathies&quot; and &quot;spondyloarthritis&quot; are currently used indistinctly as a generic designation for any of the diseases that make up the group of SpA. This guideline preferentially uses the term &quot;spondyloarthritis&quot; because it better reflects the spinal and peripheral inflammatory nature of this disease group, and because it is the term most widely used in the specialty literature at this time.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Dermatology" /><FieldValue Value="Family Practice" /><FieldValue Value="Gastroenterology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Ophthalmology" /><FieldValue Value="Physical Medicine and Rehabilitation" /><FieldValue Value="Rheumatology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide explicit recommendations easily understood by users with the defined intention of influencing clinical practice &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To reduce the variability in the management of spondyloarthritis (SpA), improving the quality of care by offering physicians who treat these patients practical recommendations adapted to their setting and based on the best, most up-to-date available evidence on the comprehensive management of SpA &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults with spondyloarthritis (SpA) or suspected spondyloarthritis&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: This guideline will not refer to SpA in children.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Early diagnosis and referral to rheumatologist &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of classification criteria appropriate for illness &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of patient&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Medical history &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physical examination, including musculoskeletal &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Laboratory tests (e.g., complete blood count, chemistry panel including liver profile, kidney function, calcium, acute phase reactants, urinalysis with sediment, rheumatoid factor [RF], anti-nuclear antibodies [ANA], and HLA-B27) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Radiographic study &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation during SpA follow-up&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Global assessment of disease activity and patient assessment &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Evaluation of physical function, structural damage, quality of life &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitor complications (e.g., cardiac, pulmonary, renal, neurological) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Early control of pain and inflammation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacological&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Analgesics &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nonsteroidal anti-inflammatory drugs (NSAIDs) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Glucocorticoids &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Disease-modifying antirheumatic drugs (DMARDs) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bisphosphonates &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Thalidomide &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Anti-TNF-&amp;alpha; agents &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-pharmacological&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patient education &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Lifestyle modifications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Rehabilitation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise, according to disease stage &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physical measures (e.g., transcutaneous electrical nerve stimulation, thermotherapy) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Manual therapies (e.g., massage, manipulations) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Balneotherapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Occupational therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Orthopedic devices &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Local infiltration with glucocorticoids (intra-articular and peri-articular) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of radiosynovectomy or chemical synovectomy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of extra-articular manifestations&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Uveitis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psoriasis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Intestinal bowel disease (IBD) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity, specificity, and likelihood ratios of diagnostic tests and criteria &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Level of pain control &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rate of disease progression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment-related adverse events &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Functional status &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The systematic reviews were carried out by members of the Spanish Society of Rheumatology (SER) Working Group on Evidence-Based Rheumatology. The reviewers conducted the systematic reviews of the questions agreed by the experts, according to the usual methodology of the group (developed in each review).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A documentalist (MPR) and a coordinator (JAML) reviewed all the search strategies so that the terms used for the selection of the population, intervention, and outcomes would be homogeneous among reviews, and provided the documents selected for the review. The literature review was carried out in 2008-2009 in the following databases:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;MEDLINE (1950 to December 2009) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;EMBASE (1974 to December 2009) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cochrane Library (1993 to December 2009) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Abstracts of scientific meetings (American College of Rheumatology [ACR], EULAR) 2007-2009 &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;A search by drug group was performed. Each of these searches includes common terms referring to the disease and the types of study. The search by drug groups will be specified in each systematic review cited in the text of Espoguia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The reviews conducted are shown in Table 1 in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;5,696 titles were reviewed, and 124 articles were included in the reviews of one or more of the Key Questions.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;See Table 2, &quot;Levels of Evidence of the Oxford Center of Evidence-Based Medicine,&quot; and the accompanying explanatory notes in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Once the systematic reviews were completed, they were sent to the expert panel for their assessment and for the initial evaluation of the level of evidence supporting their recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The levels of evidence of the Oxford Centre for Evidence-Based Medicine were used to rank the level of evidence and strength of the recommendations. This classification makes it possible to calculate the strength of the recommendations and to evaluate the quality of the evidence based on the best study design for the question.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus (Delphi)" /><FieldValue Value="Expert Consensus (Nominal Group Technique)" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Methodology&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The methodology used to produce Espoguia is appropriate for the development of recommendations, and includes nominal groups of experts, Delphi surveys, and systematic review of the literature. The guideline was developed taking into consideration at all times the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument for the evaluation of clinical practice guidelines, as a guide for the quality of Espoguia itself.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The panelist tasks were:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To define the guideline contents and scope &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To develop the recommendations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To develop the definitions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To review and contribute to the synthesis of the evidence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To write about unanticipated aspects that might emerge in developing the guideline (GPC) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Nominal Group to Establish the Scope, Definitions, and Tasks&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once the panelists were selected and had agreed to participate, a nominal group meeting was convened. In this meeting the GPC methodology was presented, including a theoretical introduction on the difference between recommendations, consensus statements and GPC, and the AGREE instrument. Panelists were also asked to come to the meeting prepared to establish the objective, users, organization, and needs for the literature review. To establish each of these aspects a secret vote was taken during the meeting, and agreement of over 60% was accepted as consensus.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At the first meeting all panelists received an editorial guideline as well as a document containing an update of all existing systematic reviews, GPCs, and consensus statements in the field of spondyloarthritis (SpA) management and treatment:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Recommendations for the treatment of ankylosing spondylitis (AS), both from the Assessment of SpondyloArthritis International Society (ASAS)/European League Against Rheumatism (EULAR) and from 3E Initiatives in Rheumatology &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical guidelines and consensus statements on anti-tumor necrosis factor alpha (anti-TNF-&amp;alpha;) therapy in AS and psoriatic arthritis (PsA) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommendations for the treatment of SpA &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cochrane reviews of SpA &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Preparation of the First Draft of Espoguia&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The panelists began to write their corresponding chapters immediately after the nominal group meeting. A coordinator and two collaborators were assigned for each chapter.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Panelists were asked to write their recommendations so as to provide practical, specific advice on the subject treated. They were specifically asked to make their recommendations based on the risk/benefit balance for the patient, and not to take costs into account in their considerations. That is, the recommendation should be made thinking always of what would be most appropriate for the patient, consistent with the objective of improving the quality of care.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Development of the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At the same time as the systematic reviews were being conducted, the expert panel was asked to make recommendations for their corresponding chapter.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;These recommendations were compiled in a working document, and the panelists were asked to give their opinion or to clarify specific aspects of the recommendation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once the reviews were completed, they were sent to the expert panel for their assessment and for the initial evaluation of the level of evidence supporting their recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Final Meeting and Establishment of the Strength of the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Both the experts and the reviewers were convened to discuss and come to agreement on the results of the reviews and the associated recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The levels of evidence of the Oxford Centre for Evidence-Based Medicine were used to rank the level of evidence and strength of the recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Another objective of this meeting was to quantify the level of agreement among the experts about each recommendation, as well as the consensus among them. These measures were determined using the Delphi method based on anonymous online surveys.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;See Table 2, &quot;Levels of Evidence of the Oxford Center of Evidence-Based Medicine,&quot; and the accompanying explanatory notes in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;It should be noted that the total mean cost (including direct and indirect costs) of ankylosing spondylitis (AS) in Spain has been estimated at about &amp;euro;7,920 per patient per year, and &amp;euro;75,000 in cases of poor evolution or severe disease.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;On completion of the clinical practice guideline, it was sent for evaluation to external reviewers: a rheumatologist expert in this clinical area (JLFS) and a methodologist expert in developing clinical practice guidelines (MGM).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions for the levels of evidence (1-5) and the grades of recommendations (A-D) are provided in Table 2 of the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Suspected Spondyloarthritis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 1&lt;/strong&gt;&lt;/span&gt;. Inflammatory back pain and oligoperipheral arthritis, especially of the lower limbs, should be considered key data for suspected spondyloarthritis (SpA) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 2&lt;/strong&gt;&lt;/span&gt;. Inflammatory back pain should be defined as back pain meeting &amp;ge;4 of the following criteria: 1) appearance before age 40, 2) insidious onset, 3) improvement with exercise, 4) no improvement with rest, 5) nocturnal pain &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Early Diagnosis of SpA&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 3&lt;/strong&gt;&lt;/span&gt;. Early diagnosis of patients with SpA should be considered a priority in rheumatology care &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;The Detection of SpA in Primary Care&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 4&lt;/strong&gt;&lt;/span&gt;. Activities/strategies/plans should be created and implemented to promote knowledge of SpA and cooperation between primary care physicians and rheumatologists in order to establish appropriate referral criteria for these patients &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Referral Criteria&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 5&lt;/strong&gt;&lt;/span&gt;. Referral to the rheumatologist as quickly as possible is recommended for patients under age 45 with a) inflammatory back pain, b) asymmetric arthritis with preferential involvement of the lower limbs, enthesitis, dactylitis, or c) rachialgia or arthralgias + 1 of: psoriasis; inflammatory bowel disease (IBD); anterior uveitis; family history of SpA, psoriasis, IBD or anterior uveitis; radiographic sacroiliitis; or human leukocyte antigen (HLA)-B27+ &lt;strong&gt;[5, D]&lt;/strong&gt;. (See Table 4, &quot;Criteria for Referral from Primary Care to the Rheumatologist,&quot; in the original guideline document.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Utility of Clinical, Laboratory, and Imaging Data for Early Diagnosis of SpA&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 6&lt;/strong&gt;&lt;/span&gt;. The use of computerized tomography for the early diagnosis of SpA is not recommended &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 7&lt;/span&gt;&lt;/strong&gt;. In cases of diagnostic uncertainty in patients strongly suspected of having SpA (including plain radiography without suggestive changes, HLA-B27 and other clinical parameters), an ultrasound study by experts can be recommended to assess both the number and degree of involvement of the entheses &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 8&lt;/strong&gt;&lt;/span&gt;. Bone scintigraphy for the early diagnosis of SpA is not recommended &lt;strong&gt;[2a, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 9&lt;/strong&gt;&lt;/span&gt;. In cases of diagnostic uncertainty in patients strongly suspected of having SpA (including plain radiography without suggestive changes, HLA-B27 and other clinical parameters), magnetic resonance imaging (MRI) of the sacroiliac joints can be recommended &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 10&lt;/strong&gt;&lt;/span&gt;. Only acute inflammatory changes (edema/osteitis) that are clearly evident on MRI of the sacroiliac joints should be considered for the diagnosis of SpA &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Diagnostic Criteria in SpA&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Modified New York Criteria for the Diagnosis of Ankylosing Spondylitis (AS)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 11&lt;/span&gt;&lt;/strong&gt;. Despite its limitations for early diagnosis, the modified New York criteria are recommended for the diagnosis of AS &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 6 in the original guideline for the modified New York criteria.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Amor and European Study Group (ESSG) for the Diagnosis of SpA&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 12&lt;/span&gt;&lt;/strong&gt;. Neither the European Study Group for Spondyloarthropathies (ESSG) nor the Amor criteria are recommended for the classification of SpA&lt;strong&gt; [2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Ankylosing Spondylitis Assessment Study (ASAS) Group Diagnostic Criteria for Axial SpA&lt;/em&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 13&lt;/strong&gt;&lt;/span&gt;. The ASAS group criteria are recommended for the diagnosis of axial SpA &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 9 in the original guideline document for the classification criteria of the ASAS group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Diagnostic Criteria for Reactive Arthritis (ReA)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 14&lt;/strong&gt;&lt;/span&gt;. The Berlin 1999 criteria are recommended for the diagnosis of ReA &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 14 in the original guideline document for the 1999 Berlin criteria.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Diagnostic Criteria for Psoriatic Arthritis (PsA)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 15&lt;/strong&gt;&lt;/span&gt;. The rheumatologist's clinical judgment or the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria should be followed for the diagnosis of PsA (if it is predominantly peripheral) and the criteria of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) group for the diagnosis of axial involvement &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Tables 12 and 13 in the original guideline document for the CASPAR and GRAPPA criteria.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Evaluation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;General Considerations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 16&lt;/strong&gt;&lt;/span&gt;. Patients with SpA should be evaluated indefinitely, except for certain cases such as some ReA patients who appear to have complete disease remission &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 17&lt;/strong&gt;&lt;/span&gt;. All evaluations of patients with SpA should include a minimum set of parameters (which may vary depending on the type of SpA) that permit assessment of inflammatory activity, function, structural damage, and treatment response and toxicity; other disease domains can optionally be included in the patient assessment &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 18&lt;/strong&gt;&lt;/span&gt;. The use of specific forms, preferably in electronic format, is recommended, as they facilitate systematic collection of data on patients with SpA &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;First Assessment of the Patient with SpA or Suspected SpA&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 19&lt;/strong&gt;&lt;/span&gt;. The first assessment of a patient with SpA or suspected SpA should include: medical history, physical examination, laboratory tests (at a minimum: complete blood count, chemistry panel, erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], immunology), radiological study, assessment of prognosis and treatment (if prescribed) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Medical History&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 20&lt;/strong&gt;&lt;/span&gt;. The medical history of patients with SpA should include: family and personal history, sociodemographic data, previous history of the disease, current symptoms and treatments (previous and concomitant) &lt;strong&gt;[5, D]&lt;/strong&gt;. (See original guideline document for more information on the variables to be collected in SPA medical history.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Physical Examination&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 21&lt;/span&gt;&lt;/strong&gt;. Besides the general examination of organs and systems, the physical examination in SpA patients should include a detailed assessment of the musculoskeletal system &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 18 in the original guideline document for a summary of elements to include in the physical exam for SpA.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Examination of the Axial Skeleton&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 22&lt;/strong&gt;&lt;/span&gt;. Examination of the cervical, dorsal and lumbar spine is recommended in all SpA patients to detect the presence of pain on palpation/manipulation, paravertebral muscle tone, swelling or deformities. Correct assessment of spinal mobility is especially important &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 20 in the original guideline document for a description of examination of the axial skeleton and hips, together with specific tests.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Joint Examination&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 23&lt;/strong&gt;&lt;/span&gt;. Examination of 44 to 78 joints is recommended, depending on the type of SpA, noting the presence of swelling on palpation, periarticular muscle tone, mobility, gait, and presence of deformities &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 21 in the original guideline document for maneuvers in examination of the sacroiliac joints and hips.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assessment of Entheses&lt;/span&gt; &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 24&lt;/span&gt;&lt;/strong&gt;. The entheses should be assessed in all patients with SpA, using one of the available instruments &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 22 in the original guideline document for location of the entheses to be evaluated with the different assessment instruments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Assessment of Dactylitis&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 25&lt;/strong&gt;&lt;/span&gt;. All patients with SpA should be evaluated for dactylitis, noting whether it is present or absent, and if it is acute or chronic &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Laboratory Tests&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 26&lt;/span&gt;&lt;/strong&gt;. At the first assessment of patients with SpA, the following laboratory tests are recommended: a complete blood count, basic chemistry panel including liver profile (glutamate oxaloacetate transaminase [GOT], glutamic-pyruvic transaminase [GPT], gamma glutamyl transferase [GGT], phosphatase, alkaline, albumin), kidney function (creatinine), calcium, acute phase reactants (ESR, CRP), urinalysis with sediment, rheumatoid factor (RF), antinuclear antibody (ANA), and HLA-B27 &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Radiographic Study and Other Imaging Techniques&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 27&lt;/strong&gt;&lt;/span&gt;. The initial baseline radiological examination should include plain radiographs (X-rays), the localization of which will vary according to the type of SpA. They include: posterior-anterior (PA) projection of the pelvis (sacroiliac joints and hips), PA and lateral projection of the three segments of the vertebral column, the chest, and peripheral joints &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Evaluation of Prognosis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 28&lt;/strong&gt;&lt;/span&gt;. Prognosis should be evaluated at each visit of the patient with SpA (in the first visit, with the data available at that time), which should include sociodemographic, socioeconomic, and work-related factors, genetic markers (if accessible), disease-dependent factors, treatment and psychological factors &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 24 in the original guideline document for prognostic factors in spondyloarthritis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evaluation During SpA Follow-up&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 29&lt;/span&gt;&lt;/strong&gt;. Patients with SpA should be evaluated at least once a year; this interval can be modified according to the type and severity of SpA, patient characteristics, and type and strategy of treatment &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 30&lt;/span&gt;&lt;/strong&gt;. Follow-up of the SpA patient should be systematized and should include collection of socioeconomic, clinical, laboratory, and radiological data, as well as treatment response/toxicity &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 25 in the original guideline document for the minimum set of variables to be collected during follow-up of spondyloarthritis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Measurement Instruments for Assessment of Each Domain&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Evaluation of Inflammatory Activity&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 31&lt;/strong&gt;&lt;/span&gt;. To evaluate inflammatory activity, the following is recommended: assessment of back pain (overall and nocturnal), patient global assessment (PtGA), physician global assessment (PhGA), swollen joint count, and enthesopathies (including dactylitis), and acute phase reactants &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Evaluation of Spinal Pain&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 32&lt;/span&gt;&lt;/strong&gt;. Both overall and nocturnal spinal pain should be evaluated separately, using a 10 cm horizontal scale divided into 10 equal 1-cm segments, with numerical descriptors from 0 to 10 and labels at each end indicating &quot;No pain&quot; (0) and &quot;Worst pain&quot; (10) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Figure 5 in the original guideline document for recommended scale for pain assessment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Patient Global Disease Assessment (Numerical Rating Scale)&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 33&lt;/span&gt;&lt;/strong&gt;. The patient global assessment of disease activity should be measured using a 10 cm horizontal scale divided into 10 equal 1-cm segments, with numerical descriptors from 0 to 10 and labels at each end indicating &quot;No activity&quot; (0) and &quot;Highest activity&quot; (10) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Figure 6 in the original guideline document for recommended scale for patient global disease assessment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Physician Global Disease Assessment&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 34&lt;/strong&gt;&lt;/span&gt;. The physician global assessment of disease activity should be measured using a 10 cm horizontal scale divided into 10 equal 1-cm segments, with numerical descriptors from 0 to 10 and labels at each end indicating &quot;No activity&quot; (0) and &quot;Highest activity&quot; (10) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Figure 7 in the original guideline document for recommended scale for physician global disease assessment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Patient Global Disease Assessment (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI])&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 35&lt;/strong&gt;&lt;/span&gt;. The patient global disease assessment should be measured using the BASDAI questionnaire &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Figure 8 in the original guideline document for BASDAI using a numerical scale.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Evaluation of Physical Function&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Bath Ankylosing Spondylitis Functional Index (BASFI)&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 36&lt;/strong&gt;&lt;/span&gt;. The BASFI is recommended as an instrument to evaluate physical function &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Figure 9 in the original guideline document for BASFI using a numerical scale.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Other Evaluation Instruments&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Evaluation of Quality of Life&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 37&lt;/strong&gt;&lt;/span&gt;. For those interested in evaluating the quality of life of patients with SpA, the use of either validated generic questionnaires like the SF (short form)-12 or specific questionnaires like the Ankylosing Spondylitis Quality of Life (ASQoL) or Psoriatic Arthritis Quality of Life (PsAQoL) are recommended &lt;strong&gt;[5, D]&lt;/strong&gt;. (See the original guideline document for more information, including questionnaires on ASQoL and PsAQoL.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Comorbidity in SpA&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 38&lt;/strong&gt;&lt;/span&gt;. The rheumatologist should monitor and control SpA-associated comorbidity, in collaboration with the primary care physician and other specialists if needed, and should seek the active participation of patients themselves &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Complications of SpA&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 39&lt;/strong&gt;&lt;/span&gt;. Extra-articular manifestations (like uveitis, IBD, or psoriasis) should be ruled out in all patients with SpA &lt;strong&gt;[5, D]&lt;/strong&gt;. Informing the patient in this respect can be very helpful for early diagnosis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Cardiac Complications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 40&lt;/strong&gt;&lt;/span&gt;. A systematic search for possible cardiac complications by complementary tests is not recommended in the absence of clinical manifestations or other factors indicating such complications &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pulmonary Complications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 41&lt;/span&gt;&lt;/strong&gt;. A systematic search for possible pulmonary complications by complementary tests is not recommended in the absence of clinical manifestations or other factors indicating such complications &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Renal Complications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 42&lt;/strong&gt;&lt;/span&gt;. In patients with SpA, routine kidney function tests, urinalysis, and monitoring of blood pressure are recommended in accordance with the characteristics of each case (inflammatory activity, treatment, age, associated comorbidities, etc.) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Neurological Complications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 43&lt;/strong&gt;&lt;/span&gt;. Careful assessment of any neurological sign is recommended in patients with SpA &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Comorbidity Not Directly Related to SpA&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Osteoporosis&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 44&lt;/strong&gt;&lt;/span&gt;. Physicians should be aware of the possibility that SpA patients may develop osteoporosis. The need for additional tests to diagnose this condition should be assessed depending on the risk factors and clinical characteristics of each case &lt;strong&gt;[5, D]&lt;/strong&gt;. Interpretation of the lumbar bone mineral densitometry may be difficult if calcifications are present in the spinal entheses; hip densitometry should be assessed if this is the case &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Cardiovascular Comorbidity&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 45&lt;/strong&gt;&lt;/span&gt;. In patients with SpA, inflammatory disease activity should be reduced to the maximum extent possible, and the traditional disease factors should be adequately controlled &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Pharmacological Treatment&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;General Considerations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 46&lt;/strong&gt;&lt;/span&gt;. SpA treatment should be adjusted to the clinical manifestations of the disease, severity of the symptoms, other clinical findings, and prognostic factors, as well as general patient characteristics (age, sex, comorbidity, etc.), preferences and expectations &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 47&lt;/strong&gt;&lt;/span&gt;. Optimal management of SpA patients requires a combination of pharmacological and non-pharmacological treatments which should be started as early as possible &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Objective of Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 48&lt;/strong&gt;&lt;/span&gt;. The goal of SpA treatment is disease remission or, failing that, the maximum possible reduction of inflammation in order to achieve significant improvement of signs and symptoms (joint inflammation, pain, axial and peripheral stiffness, etc.), preserve functional capacity, maintain good quality of life, and control structural damage &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Drugs (Efficacy and Safety)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Analgesics&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 49&lt;/strong&gt;&lt;/span&gt;. Analgesics like paracetamol or opiates can be offered to patients with SpA whose pain is not controlled with non-steroidal anti-inflammatory drugs (NSAIDs), or when NSAIDs are contraindicated or poorly tolerated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Nonsteroidal Anti-Inflammatory Drugs&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 50&lt;/strong&gt;&lt;/span&gt;. The NSAIDs are recommended (unless contraindicated) as first-line treatment for the control of pain and stiffness and to improve function in patients with SpA &lt;strong&gt;[1b, A]&lt;/strong&gt;. Once the therapeutic goal is achieved, the minimum effective dose should be maintained &lt;strong&gt;[5, D]&lt;/strong&gt;. Before considering an NSAID to be ineffective, it should have been administered for at least 2-4 weeks at the maximum recommended or tolerated doses &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Glucocorticoids&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 51&lt;/strong&gt;&lt;/span&gt;. Local glucocorticoids (GC) infiltrations are recommended in SpA patients refractory to NSAIDs &lt;strong&gt;[1c, A]&lt;/strong&gt;. The use of systemic GCs is recommended only in exceptional situations of major inflammation &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Disease-Modifying Antirheumatic Drugs (DMARDs)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 52&lt;/span&gt;.&lt;/strong&gt; In SpA patients who are refractory to NSAIDs, the use of DMARDs should be evaluated &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Sulfasalazine&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 53&lt;/strong&gt;&lt;/span&gt;. Routine use of sulfasalazine (SSZ) is not recommended for treatment of axial symptoms in SpA &lt;strong&gt;[1a, A]&lt;/strong&gt;, but it is indicated in cases of peripheral involvement &lt;strong&gt;[1a, A]&lt;/strong&gt; and for other extra-articular manifestations like uveitis &lt;strong&gt;[2c, B]&lt;/strong&gt; and IBD &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Methotrexate&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 54&lt;/strong&gt;&lt;/span&gt;. The use of methotrexate (MTX) should be evaluated individually in patients with AS, undifferentiated SpA (uSpA) or reactive arthritis (ReA) (especially peripheral forms and enthesitis) who are refractory to all available treatments with proven efficacy &lt;strong&gt;[5, D]&lt;/strong&gt;. MTX should be assessed for routine use in PsA &lt;strong&gt;[2a, B]&lt;/strong&gt; and in extra-articular manifestations like uveitis &lt;strong&gt;[2c, B]&lt;/strong&gt; and IBD &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Leflunomide&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 55&lt;/strong&gt;&lt;/span&gt;. The use of leflunomide (LEF) should be evaluated individually in patients with AS, uSpA and ReA (especially in peripheral forms and enthesitis), and extra-articular manifestations refractory to all available treatments with proven efficacy &lt;strong&gt;[5, D]&lt;/strong&gt;. LEF should be assessed for routine use in PsA for peripheral arthritis and dactylitis &lt;strong&gt;[1b, A]&lt;/strong&gt;, and enthesitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Cyclosporin A&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 56&lt;/strong&gt;&lt;/span&gt;. The use of cyclosporin A (CsA) should be evaluated individually in patients with AS, uSpA and ReA (especially in peripheral forms and enthesitis), refractory to all available treatments with proven effectiveness &lt;strong&gt;[5, D]&lt;/strong&gt;. Its use should be assessed in extraarticular manifestations &lt;strong&gt;[2b, B]&lt;/strong&gt; and in PsA for peripheral arthritis and dactylitis &lt;strong&gt;[2b, B]&lt;/strong&gt;, and enthesitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Other DMARDs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 57&lt;/strong&gt;&lt;/span&gt;. SpA patients who are clinically active and in whom other treatments have failed or are not possible should be evaluated individually for possible use of azathioprine (AZA), gold salts, cyclophosphamide, or d-penicillamine provided that the potential benefit is considered to outweigh the possible adverse events &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Other Pharmacological Treatments (Efficacy and Safety)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Bisphosphonates&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 58&lt;/strong&gt;&lt;/span&gt;. Pamidronate may be offered in selected cases to SpA patients who are refractory to conventional treatments and in whom initiation of anti-TNF therapy is contraindicated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Thalidomide&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 59&lt;/strong&gt;&lt;/span&gt;. SpA patients with particularly severe axial involvement and who are refractory to all therapies with proven efficacy should be evaluated individually for possible use of thalidomide, with special attention to its toxicity profile &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment Changes and Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 60&lt;/strong&gt;&lt;/span&gt;. Whenever the therapeutic goal is not attained, the patient's treatment should be reevaluated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 61&lt;/strong&gt;&lt;/span&gt;. The recommended variables for evaluation of treatment response in SpA are the BASDAI, PtGA, nocturnal spinal pain, arthritis/enthesitis, the Disease Activity Score-28 (DAS-28), and acute phase reactants (APRs) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Patients without Previous Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 62&lt;/strong&gt;&lt;/span&gt;. In SpA, it is recommended that pharmacological treatment be evaluated at 3-4 months &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 63&lt;/strong&gt;&lt;/span&gt;. In patients with predominantly axial SpA, anti-TNF-&amp;alpha; agents should be used if, after 3 months of NSAID treatment, the BASDAI remains &amp;ge;4, together with at least one of the following criteria: a) PtGA &amp;ge;4; b) nocturnal pain &amp;ge;4; c) elevated APR. In any case, the opinion of a rheumatologist or physician expert in SpA is essential &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 64&lt;/strong&gt;&lt;/span&gt;. For peripheral forms of SpA, the anti-TNF-&amp;alpha; are indicated if, despite treatment with at least two NSAIDs, SSZ (AS and PsA), or other DMARDs (PsA) and local treatments, arthritis or enthesitis persist for more than 3-4 months, in addition to PtGA &amp;ge;4 and/or elevated ESR/CRP and, for pure polyarticular arthritis, if the patient's DAS-28 is &amp;ge;3.2 &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 65&lt;/strong&gt;&lt;/span&gt;. In SpA, certain conditions such as monoarthritis, enthesitis, or some extra-articular manifestations refractory to conventional treatment which have a pronounced functional or other type of impact on the patient, must be considered as treatment failure &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Patients with Previous Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 66&lt;/strong&gt;&lt;/span&gt;. In SpA patients who are considered not to have been treated correctly, treatment should be restarted or completed correctly before an anti-TNF-&amp;alpha; is indicated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 67&lt;/strong&gt;&lt;/span&gt;. In patients with SpA who responded to a DMARD that was subsequently withdrawn, in case of a new flare-up, the same DMARD should be prescribed before indicating an anti-TNF-&amp;alpha; &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Evaluation of Response to TNF&amp;alpha; Antagonist Agents&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 68&lt;/strong&gt;&lt;/span&gt;. A patient with SpA and axial involvement will be considered to respond to anti-TNF-&amp;alpha; if, after 3-4 months of treatment, disease remission is achieved or there is a 50% relative decrease on the BASDAI (or an absolute reduction of 2 points with respect to previous values) in at least one of the following: PtGA, nocturnal axial pain (if both were &amp;gt;4 before treatment), or reduction in ESR and/or CRP (if they were previously elevated) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 69&lt;/span&gt;&lt;/strong&gt;. SpA patients with axial involvement who have not responded to one anti-TNF-&amp;alpha; can switch to a second anti-TNF-&amp;alpha; &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 70&lt;/strong&gt;&lt;/span&gt;. In SpA patients with axial involvement, if the response achieved with the second anti-TNF-&amp;alpha; is &amp;lt;50% but &amp;gt;20% on the BASDAI and the PtGA, since the most effective therapeutic options currently available will have been used, treatment with the biological agent that the clinician considers of choice should be maintained unless one of the nonbiological treatments previously used would have been more effective, in which case consideration should be given to reinstating that treatment &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 71&lt;/strong&gt;&lt;/span&gt;. In SpA patients with axial involvement, if the response achieved with the second anti-TNF-&amp;alpha; is &amp;lt;20% on the BASDAI and PtGA, the anti-TNF-&amp;alpha; should be withdrawn if deemed advisable by the physician &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 72&lt;/strong&gt;&lt;/span&gt;. SpA patients with peripheral polyarticular involvement who are taking an anti-TNF-&amp;alpha; agent should achieve clinical remission (DAS28 &amp;lt;2.6) or at least reduce inflammatory activity to DAS28 &amp;lt;3.2. When this is not achieved, a DAS reduction of 1.2 (from the previous level) would be accepted as sufficient to maintain treatment with the anti-TNF-&amp;alpha; that the clinician considers to be of choice, unless one of the non-biological treatments previously used would have been more effective, in which case its reinstatement should be considered &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment of Pain&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 73&lt;/strong&gt;&lt;/span&gt;. Control of pain is essential from the time of symptom onset in SpA, with NSAIDs being the treatment of choice &lt;strong&gt;[1b, A]&lt;/strong&gt;. Analgesics can be used if the response to NSAIDs is insufficient or if there is intolerance or contraindication to their use &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 74&lt;/strong&gt;&lt;/span&gt;. In SpA, paracetamol at a dosage of 3-4 g/day is considered the analgesic of choice &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;SpA Treatment in Special Situations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Elderly Patients&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 75&lt;/strong&gt;&lt;/span&gt;. When making treatment decisions for elderly patients with SpA, changes in pharmacokinetics and pharmacodynamics typical of increased age should be kept clearly in mind &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 76&lt;/strong&gt;&lt;/span&gt;. Strict monitoring of kidney and liver function is recommended in elderly patients with SpA, as well as adjustment of the dosage of drugs eliminated by these routes &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 77&lt;/strong&gt;&lt;/span&gt;. In elderly patients with SpA and immunosuppressive treatments, the possible appearance of adverse events and interactions with their usual drugs should be strictly monitored &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 78&lt;/span&gt;&lt;/strong&gt;. In elderly SpA patients treated with biological therapies, strict monitoring of possible related adverse events is recommended, with special attention to infections, neoplasia, and heart failure &lt;strong&gt;[4, C]&lt;/strong&gt;. It is also recommended to follow the same indications for vaccination as for the young adult population &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pregnancy, Breastfeeding, and Fertility&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Pregnancy and Breastfeeding&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 79&lt;/strong&gt;&lt;/span&gt;. Patients of childbearing age (both men and women) should be informed of the possible effects of SpA with regard to fertility, pregnancy and breastfeeding, and in particular of the effect of their drug treatments in these areas &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 80&lt;/span&gt;&lt;/strong&gt;. Controlled use of NSAIDs is recommended in SpA patients during pregnancy in cases where this is justified, and they should be discontinued 6-8 weeks before delivery; during the lactation period, they should be taken while breastfeeding &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 81&lt;/span&gt;&lt;/strong&gt;. In SpA patients, it is recommended that GCs (preferably prednisone, [methyl]prednisolone, cortisone, or hydrocortisone) be used during pregnancy only in justified cases and under close control. High doses should be avoided (especially in the first trimester), and a stress dose should be used during delivery &lt;strong&gt;[4, C]&lt;/strong&gt;. If high doses of GCs are required during lactation, it is suggested that women should breastfeed 4 hours after the last dose &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 82&lt;/strong&gt;&lt;/span&gt;. Thalidomide is contraindicated in SpA patients during pregnancy &lt;strong&gt;[2b, B]&lt;/strong&gt;. and its use during breastfeeding is not recommended &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 83&lt;/strong&gt;&lt;/span&gt;. The use of pamidronate in SpA patients should be evaluated individually during pregnancy and lactation, reserving it for those cases in which the benefit of the therapy clearly outweighs the possible toxic effects &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 84&lt;/strong&gt;&lt;/span&gt;. The use of antimalarials (preferably hydroxychloroquine, at doses routinely used in rheumatology) should be evaluated individually in SpA patients during pregnancy and lactation, reserving it for those cases in which the benefit of therapy clearly outweighs its possible toxic effects &lt;strong&gt;[3b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 85&lt;/strong&gt;&lt;/span&gt;. MTX is contraindicated in SpA patients during pregnancy and lactation &lt;strong&gt;[2b, B]&lt;/strong&gt;. Contraceptive measures should be used during treatment in both men and women, and treatment should be discontinued 3-4 months before conception &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 86&lt;/strong&gt;&lt;/span&gt;. The use of CsA should be evaluated individually in SpA patients during pregnancy, reserving it for those cases in which the benefit of therapy clearly outweighs the possible toxic effects &lt;strong&gt;[2b, B]&lt;/strong&gt;. Its use during breastfeeding is not recommended &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 87&lt;/strong&gt;&lt;/span&gt;. The use of mycophenolate mofetil should be evaluated individually in SpA patients during pregnancy, reserving it for those cases in which the benefit of therapy clearly outweighs the possible toxic effects &lt;strong&gt;[2b, B]&lt;/strong&gt;. Treatment should be discontinued 6 weeks before conception &lt;strong&gt;[5, D]&lt;/strong&gt;. Its use during breastfeeding is not recommended &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 88&lt;/strong&gt;&lt;/span&gt;. The use of SSZ (at doses of &amp;le;2 g/day) in SpA patients during pregnancy should be closely controlled and administered only in cases where it is justified &lt;strong&gt;[2b, B]&lt;/strong&gt;. It should be discontinued during one complete menstrual cycle before conception in women (if not considered necessary during the pregnancy) and 2-3 months before conception in men &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 89&lt;/strong&gt;&lt;/span&gt;. LEF is contraindicated in SpA patients during pregnancy and lactation. Contraceptive measures should be used (in both men and women) before beginning treatment. In case of pregnancy and/or if a male wishes to have children, it should be discontinued immediately, and treatment should be started with cholestyramine at 8 g 3 times a day for 11 days, until reaching LEF plasma levels of &amp;lt;0.02 mg/l in two tests conducted 2 weeks apart; couples should then wait 3 months before conception &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 90&lt;/span&gt;&lt;/strong&gt;. Gold salts are not recommended in SpA patients during pregnancy and lactation &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 91&lt;/strong&gt;&lt;/span&gt;. D-penicillamine is contraindicated in SpA patients during pregnancy and lactation &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 92&lt;/span&gt;&lt;/strong&gt;. The use of AZA should be evaluated individually in SpA patients during pregnancy, reserving it for those cases in which the benefit of the therapy clearly outweighs the possible toxic effects &lt;strong&gt;[4, C]&lt;/strong&gt;. Its use during lactation is not recommended &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 93&lt;/strong&gt;&lt;/span&gt;. The use of cyclophosphamide should be evaluated individually in SpA patients during pregnancy; it should be avoided in the first trimester and reserved for those cases in which the benefit of the therapy clearly outweighs the possible toxic effects &lt;strong&gt;[2b, B]&lt;/strong&gt;. Its use during lactation is not recommended &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 94&lt;/strong&gt;&lt;/span&gt;. The use of biological therapy should be evaluated individually in SpA patients during pregnancy, reserving it for those cases in which the benefit of the therapy clearly outweighs the possible toxic effects &lt;strong&gt;[2a, B]&lt;/strong&gt;. Its use during lactation is not recommended &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Secondary Amyloidosis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 95&lt;/strong&gt;&lt;/span&gt;. In patients with SpA and secondary amyloidosis, strict control of the underlying disease is recommended, as well as periodic monitoring of the levels of serum amyloid A protein &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 96&lt;/strong&gt;&lt;/span&gt;. In patients with long-term SpA, deterioration of renal function and/or development of proteinuria not explained by any other cause should lead the clinician to suspect a possible case of secondary amyloidosis &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Enthesitis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 97&lt;/strong&gt;&lt;/span&gt;. The recommended treatments of choice in SpA are NSAIDs &lt;strong&gt;[2b, B]&lt;/strong&gt;, physical therapy, and ortheses &lt;strong&gt;[3b, B]&lt;/strong&gt;. Local infiltrations of GCs may be considered in cases that are refractory/intolerant to NSAIDs &lt;strong&gt;[4, C]&lt;/strong&gt;. If all these fail, the use of anti-TNF may be considered &lt;strong&gt;[1b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Undifferentiated Spondyloarthritis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 98&lt;/strong&gt;&lt;/span&gt;. Early control of pain and inflammation is essential in patients with uSpA. It should be treated with drugs of proven efficacy in the established forms of SpA, and response to treatment should be monitored individually &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Reactive Arthritis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 99&lt;/strong&gt;&lt;/span&gt;. Patients with suspected ReA and urethritis or cervicitis should be tested for &lt;em&gt;Chlamydia trachomatis&lt;/em&gt; in the urine, or in urethral or cervical exudate, and patients with diarrhea should be tested for enterobacterias in feces and serum &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 100&lt;/strong&gt;&lt;/span&gt;. NSAIDs are recommended in the acute phases of ReA &lt;strong&gt;[2b, B]&lt;/strong&gt;, and use of GCs (oral or infiltrations) should be considered in cases of severe inflammation &lt;strong&gt;[5, D]&lt;/strong&gt;. Patients who are refractory or intolerant to these treatments, or who have chronic involvement or erosive disease, should begin DMARD treatment &lt;strong&gt;[2b, B]&lt;/strong&gt;. If symptoms persist, consider treatment with an anti-TNF-&amp;alpha; agent &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antibiotic Therapy&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 101&lt;/span&gt;&lt;/strong&gt;. Antibiotic treatment in ReA is indicated in patients with acute genitourinary infection from &lt;em&gt;Chlamydia&lt;/em&gt;, or with a previously documented untreated infection, but it is not recommended in patients with established ReA &lt;strong&gt;[1c, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Other Treatments&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Education and Lifestyle Modification&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Education&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 102&lt;/strong&gt;&lt;/span&gt;. Patients with SpA should be informed about all aspects of their disease, including its evolution and all aspects of their treatment &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Lifestyle Changes&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 103&lt;/strong&gt;&lt;/span&gt;. Patients with SpA should be advised to stop smoking &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rehabilitation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Exercise Programs&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 104&lt;/strong&gt;&lt;/span&gt;. Exercise programs should be an important part of SpA treatment since they improve physical function, flexibility, and overall feelings of wellbeing &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendations According to Disease Stage&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 105&lt;/strong&gt;&lt;/span&gt;. A program of aerobic exercise is recommended in early stages of disease &lt;strong&gt;[2b, B]&lt;/strong&gt;. When the patient has partial limitation of mobility, stretching exercises should be added &lt;strong&gt;[1b, A]&lt;/strong&gt;. In cases that progress to ankylosis, aerobic and strengthening exercises can be combined &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Strategies to Improve Adherence&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 106&lt;/strong&gt;&lt;/span&gt;. For maximum effectiveness, strategies should be used to improve adherence (education, initial supervision, patient associations, etc.) &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Physical Measures&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 107&lt;/strong&gt;&lt;/span&gt;. Application of physical agents (transcutaneous electrical nerve stimulation [TENS], thermotherapy, etc.) to symptomatic regions may improve pain and the feeling of stiffness in some patients &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Manual Therapies&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 108&lt;/strong&gt;&lt;/span&gt;. Spinal manipulations are absolutely contraindicated in patients with advanced AS who have active inflammation and/or stiff or inflexible spines and/or fragile or unstable spines, especially if they are middle aged or elderly &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Balneotherapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 109&lt;/strong&gt;&lt;/span&gt;. Balneotherapy can be recommended in SpA patients without active disease when other, more accessible therapies have proven ineffective &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Occupational Therapy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 110&lt;/strong&gt;&lt;/span&gt;. Occupational therapy and prescription of assistive devices may be indicated in advanced cases when impairment begins to cause some type of functional limitation in carrying out the activities of daily living &lt;strong&gt;[1b, A]&lt;/strong&gt;. (See the original guideline document for recommendations and assistive devices for the activities of daily living.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Local and Intra-Articular Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Local Infiltrations with Glucocorticoids&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 111&lt;/strong&gt;&lt;/span&gt;. The use of local GC infiltrations (intra- or peri-articular) should be considered in SpA patients who are refractory to conventional treatments and/or who have major inflammation of the entheses and bursae &lt;strong&gt;[4, C]&lt;/strong&gt;, peripheral joints &lt;strong&gt;[5, D]&lt;/strong&gt;, and sacroiliac joints &lt;strong&gt;[1c, A]&lt;/strong&gt;; accessibility and possible side effects should always be evaluated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 112&lt;/span&gt;&lt;/strong&gt;. Infiltration with slow-release GCs is recommended &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Radioisotopic Synovectomy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 113&lt;/strong&gt;&lt;/span&gt;. The use of radiosynovectomy should be individually assessed in SpA patients with chronic synovitis producing pain and/or disability, and who are refractory to or cannot tolerate conventional treatments (including GC infiltration) &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 114&lt;/strong&gt;&lt;/span&gt;. GCs should be administered in combination with synovectomy &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 115&lt;/strong&gt;&lt;/span&gt;. Synovectomy is not recommended in AS patients who have not yet reached skeletal maturity &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Surgical Treatment in SpA&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Surgery of the Spine&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 116&lt;/span&gt;&lt;/strong&gt;. In AS patients, spinal surgery should be resorted to only in highly selected patients who have considerable pain or disability and are refractory to medical treatment &lt;strong&gt;[2c, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Hip Surgery&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 117&lt;/strong&gt;&lt;/span&gt;. Hip arthroplasty is recommended in SpA patients who have considerable pain or disability and evidence of structural damage, and who are refractory to medical treatment &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Radiation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 118&lt;/strong&gt;&lt;/span&gt;. Radiation is not recommended in the treatment of SpA &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Extra-Articular Manifestations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Uveitis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;General Considerations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 119&lt;/strong&gt;&lt;/span&gt;. Uveitis should be considered a medical emergency, and early, aggressive treatment should be started to minimize the risk of developing ocular complications &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Clinical Picture and Diagnosis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 120&lt;/strong&gt;&lt;/span&gt;. Interdisciplinary collaboration between ophthalmologists and rheumatologists is recommended, preferably jointly in uveitis units for the diagnosis, treatment, and follow-up of SpA patients with uveitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 56 in the original guideline document for the most frequent diagnoses (including ophthalmological syndromes and screening and/or complementary tests to be considered depending on type of uveitis).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 121&lt;/strong&gt;&lt;/span&gt;. SpA patients who have more than three acute anterior uveitis (AAU) flares per year should be treated with SSZ or MTX &lt;strong&gt;[2b, B]&lt;/strong&gt;. Initial treatment with biological therapies is not recommended &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Psoriasis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Diagnosis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 122&lt;/strong&gt;&lt;/span&gt;. Cutaneous psoriasis should be diagnosed by visualization of the lesions, preferably by an expert in dermatology, and histological diagnosis should be reserved for exceptional cases &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Evaluation of Psoriasis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 123&lt;/strong&gt;&lt;/span&gt;. In clinical practice, evaluation of psoriasis patients should be guided by the &quot;rule of tens,&quot; considering psoriasis to be severe when either the Psoriasis Area Severity Index (PASI), body surface area (BSA) or Dermatology Life Quality Index (DLQI) score is higher than 10 &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 124&lt;/strong&gt;&lt;/span&gt;. All psoriasis patients should maintain good skin hygiene &lt;strong&gt;[1b, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Intestinal Bowel Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Diagnosis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 125&lt;/span&gt;&lt;/strong&gt;. If there is the slightest suspicion of intestinal involvement, patients should be referred to a digestive system specialist for further study &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Ankylosing Spondylitis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Disease Course and Prognosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 126&lt;/span&gt;&lt;/strong&gt;. AS patients should be diagnosed and started on appropriate treatment as early as possible &lt;strong&gt;[1, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;First Evaluation of Patient with AS/Suspected AS&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 127&lt;/strong&gt;&lt;/span&gt;. The first evaluation of a patient with AS or suspected AS should include: a medical history, physical examination, laboratory tests (at a minimum: complete blood count, chemistry panel, ESR, CRP, HLA-B27), x-ray examination (sacroiliac joints, hips and spine), and assessment of prognosis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 60 in the original guideline for the first assessment of patient with ankylosing spondylitis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 128&lt;/span&gt;&lt;/strong&gt;. Morning back stiffness in AS patients should be evaluated in terms of its duration in minutes &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 129&lt;/span&gt;&lt;/strong&gt;. A 44-swollen joint count is recommended in AS patients &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 130&lt;/span&gt;&lt;/strong&gt;. Given the prognostic and functional importance of the hip in AS, a complete clinical evaluation of this joint should be conducted routinely &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 131&lt;/strong&gt;&lt;/span&gt;. The BASDAI should be administered to AS patients for assessment of both disease activity and response to treatment &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 132&lt;/strong&gt;&lt;/span&gt;. To evaluate function in AS patients, the BASFI is recommended as the first option; alternatively, the Dougados Functional Index (DFI) can be used &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 133&lt;/span&gt;&lt;/strong&gt;. Spinal mobility should be evaluated in AS patients (as part of the evaluation of function) using the modified Sch&amp;ouml;ber test, finger-floor distance, lateral lumbar flexion, chest expansion, occiput-wall and cervical rotation &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 134&lt;/span&gt;&lt;/strong&gt;. The entheses should be evaluated for tenderness to palpation in AS patients, following a validated enthesis index (preferably the Maastricht Ankylosing Spondylitis Enthesis Score [MASES] index) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 135&lt;/span&gt;&lt;/strong&gt;. Structural damage should be assessed in AS by plain anteroposterior (AP) radiograph of the pelvis and AP and lateral x-ray of the three segments of the spinal column, following a graduated scale based on the New York criteria (sacroiliac joints) and the Modified Stoke Ankylosing Spondylitis Score (mSASS) (spine). Additional radiographs should be considered if other joints are affected &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 136&lt;/strong&gt;&lt;/span&gt;. Both ESR and CRP should be evaluated in AS &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 137&lt;/span&gt;&lt;/strong&gt;. HLA-B27 and other biomarkers should be requested in AS patients, depending on the diagnostic uncertainty &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 138&lt;/span&gt;&lt;/strong&gt;. The prognosis in AS patients should be evaluated considering factors like male sex, early age at onset, the presence of peripheral arthritis, smoking, low educational level or low socioeconomic status, regular practice of an activity requiring intense physical effort, or lack of physical activity &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Evaluation During AS Follow-up&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 139&lt;/strong&gt;&lt;/span&gt;. Systematic follow-up of AS patients is recommended. This should include collection of socio-occupational, clinical, laboratory, and imaging data, prognoses, and treatment response/toxicity. Their frequency will depend on the type of variable and characteristics of the patient and treatment &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 61 for follow-up of patients with ankylosing spondylitis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Frequency of Monitoring in AS&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 140&lt;/strong&gt;&lt;/span&gt;. After AS is diagnosed, patients should be monitored frequently (from 2 to 4 weeks to 1.5 to 3 months) to check the evolution of disease activity and treatment response/toxicity. Subsequently, when patients are in remission, or have a low level of activity or a good therapeutic response, they should be monitored every 6 to 12 months, except for patients needing pharmacological monitoring of DMARD or anti-TNF-&amp;alpha; treatment, who should be checked every 2 to 4 months &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 141&lt;/strong&gt;&lt;/span&gt;. Cases of acute back pain, peripheral arthritis or extra-articular manifestations should be evaluated as soon as possible; and in the case of some manifestations like uveitis, emergency evaluation is recommended &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Evaluation of Response to Treatment&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 142&lt;/strong&gt;&lt;/span&gt;. The following definitions are recommended when evaluating response to treatment &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Disease remission&lt;/strong&gt;: Absence of symptoms, signs, and any other data indicative of AS activity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Disease activity&lt;/strong&gt;: The presence at 3-4 months, in axial forms, of a BASDAI &amp;ge;4 and at least one of: PtGA &amp;gt;4, nocturnal back pain &amp;gt;4, increase in acute phase reactants. In peripheral forms: persistence of arthritis and/or enthesitis in &amp;ge;1 site and at least one of: PtGA &amp;gt;4, increase in acute phase reactants.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Least possible clinical activity&lt;/strong&gt;: BASDAI &amp;le;2, PtGA &amp;lt;2; alternatively, BASDAI, PtGA and nocturnal back pain &amp;lt;4.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment Response Measures/Criteria&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 143&lt;/strong&gt;&lt;/span&gt;. The variables recommended for treatment response in AS are the BASDAI, PtGA, nocturnal back pain, arthritis/enthesitis, and acute phase reactants &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Changes in Treatment&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 144&lt;/strong&gt;&lt;/span&gt;. Whenever the therapeutic goal is not reached in AS, a treatment decision must be made &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 145&lt;/span&gt;&lt;/strong&gt;. NSAIDs should be continued at the minimum effective dose in AS patients who reach the therapeutic goal &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 146&lt;/strong&gt;&lt;/span&gt;. Axial AS should be considered as not responding to treatment if after 3-4 months of treatment at full/maximum tolerated doses of at least 2 NSAIDs, the BASDAI is &amp;ge;4 and (one of the following): PtGA &amp;ge;4, nocturnal pain &amp;ge;4 and/or the acute phase reactants are elevated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 147&lt;/strong&gt;&lt;/span&gt;. Peripheral AS should be considered as not responding to treatment if after 3-4 months of treatment at full/maximum tolerated doses of (NSAIDs and/or SSZ, local GCs and chemical synovectomy), the arthritis/enthesitis persists and the ESR &amp;ge;4 and/or the acute phase reactants are elevated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 148&lt;/strong&gt;&lt;/span&gt;. Response to an anti-TNF-&amp;alpha; agent in AS patients should be evaluated every 3-4 months, taking into account the BASDAI, PtGA, nocturnal back pain, and the acute phase reactants &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment of AS&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;General Considerations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 149&lt;/strong&gt;&lt;/span&gt;. The choice of treatment in AS should be based on disease and patient characteristics &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 67 in the original guideline document for factors on which treatment should be based in patients with AS.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pharmacological Treatment of AS&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;NSAID and Other Analgesics&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 150&lt;/strong&gt;&lt;/span&gt;. NSAIDs are the treatment of choice in AS patients &lt;strong&gt;[1b, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 151&lt;/strong&gt;&lt;/span&gt;. The Cyclooxygenase-2 (COX-2) inhibitors can be considered in AS patients who are NSAID refractory or intolerant, or in whom NSAIDs are contraindicated &lt;strong&gt;[1b, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Glucocorticoids (GCs)&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 152&lt;/strong&gt;&lt;/span&gt;. Intra- or periarticular GC infiltration can be considered as adjunctive therapy in selected patients with AS and sacroiliitis &lt;strong&gt;[1c, A]&lt;/strong&gt;, persistent monoarthritis or oligoarthritis, or enthesitis &lt;strong&gt;[5, D]&lt;/strong&gt;, so long as the possible risk of adverse events, especially tendon rupture, is continually monitored. The use of systemic GCs is recommended only in exceptional situations of major inflammation &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;DMARDs and Other Drugs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 153&lt;/span&gt;&lt;/strong&gt;. SSZ is recommended in peripheral AS &lt;strong&gt;[1a, A]&lt;/strong&gt; and in cases of uveitis &lt;strong&gt;[2c, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 154&lt;/strong&gt;&lt;/span&gt;. The use of MTX should be evaluated individually in AS patients who are refractory to all available treatments of proven efficacy (especially those with peripheral forms and enthesitis) &lt;strong&gt;[5, D]&lt;/strong&gt;, and patients with uveitis &lt;strong&gt;[2c, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 155&lt;/strong&gt;&lt;/span&gt;. The use of LEF should be evaluated individually in patients with peripheral AS who are refractory to all available treatments of proven efficacy &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 156&lt;/strong&gt;&lt;/span&gt;. The use of CsA, AZA, gold salts, cyclophosphamide and D-penicillamine should be evaluated individually in AS patients who are clinically active whenever other treatments are not possible or the remaining available therapies have failed and the potential benefit is considered to exceed the possible adverse events &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 157&lt;/strong&gt;&lt;/span&gt;. The use of thalidomide should be evaluated individually in patients with particularly severe axial AS refractory to all available therapies of proven efficacy, always keeping in mind its toxicity profile &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 158&lt;/strong&gt;&lt;/span&gt;. Pamidronate may be offered in selected cases to AS patients refractory to conventional treatments and in whom initiation of anti-TNF-&amp;alpha; therapy is contraindicated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Biological Therapy&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 159&lt;/strong&gt;&lt;/span&gt;. When use of an anti-TNF-&amp;alpha; is indicated in AS, the choice of agent is at the physician's discretion, and depends on the manifestations and circumstances particular to each patient &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 160&lt;/strong&gt;&lt;/span&gt;. The use of infliximab (IFX) is recommended in patients with axial AS who are refractory to NSAIDs and other symptomatic treatments (analgesics, local GC infiltrations), and in patients with peripheral AS who are refractory to NSAIDs, DMARDs, and symptomatic treatments (analgesics, local GC infiltrations, synoviorthesis) &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 161&lt;/strong&gt;&lt;/span&gt;. Etanercept (ETN) is recommended in axial AS patients refractory to NSAIDs and other symptomatic treatments (analgesics, local GC infiltrations), and in peripheral AS patients refractory to NSAIDs, DMARDs and symptomatic treatments (analgesics, local GC infiltrations, synoviorthesis) &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 162&lt;/strong&gt;&lt;/span&gt;. The use of adalimumab (ADA) is recommended in axial AS patients refractory to NSAIDs and other symptomatic treatments (analgesics, local GC infiltrations), and in peripheral AS patients refractory to NSAIDs, DMARDs and symptomatic treatments (analgesics, local GC infiltrations, synoviorthesis) &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Radiation Synovectomy&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 163&lt;/strong&gt;&lt;/span&gt;. Radioisotopic synovectomy should be considered in cases of AS with arthritis that is very symptomatic and/or produces major functional impairment, and which is refractory to conventional treatments including GC infiltration &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Non-Pharmacological Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Education&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 164&lt;/span&gt;&lt;/strong&gt;. Patients with AS should be informed about all aspects related to their disease, including its evolution and complete information on its treatment &lt;strong&gt;[4, C]&lt;/strong&gt;, and should be advised to stop smoking &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rehabilitation&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 165&lt;/strong&gt;&lt;/span&gt;. In AS patients, the exercise type, technique or program should be adjusted to the specific requirements of the patient's disease, characteristics, particular circumstances and preferences, as well as the available resources &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Exercise Programs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 166&lt;/strong&gt;&lt;/span&gt;. Physical exercise should be routinely indicated in AS patients &lt;strong&gt;[1b, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 167&lt;/strong&gt;&lt;/span&gt;. All available strategies should be used to increase the level of compliance with the exercise program, especially in the case of exercises done at home &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 168&lt;/strong&gt;&lt;/span&gt;. In the early phases a program of aerobic exercise is recommended. &lt;strong&gt;[2b, B]&lt;/strong&gt; When the patient develops partial limitation of mobility, stretching exercises should be added &lt;strong&gt;[1b, A]&lt;/strong&gt;. In cases that progress to ankylosis, aerobic and strengthening exercises can be combined &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Other Measures&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 169&lt;/span&gt;&lt;/strong&gt;. Spinal manipulations are absolutely contraindicated in patients with advanced AS, especially if they are of middle or advanced age, who have active inflammation and/or spinal columns that are rigid or inflexible and/or fragile or unstable &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 170&lt;/span&gt;&lt;/strong&gt;. Occupational therapy and the prescription of assistive devices may be indicated in cases of advanced AS &lt;strong&gt;[1b, A]&lt;/strong&gt;. (See Table 69 in the original guideline document for recommendations and assistive devices for the activities of daily living.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Surgical Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 171&lt;/strong&gt;&lt;/span&gt;. Surgical treatment should be indicated for AS patients with major pain and/or disability that is refractory to medical treatment &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Psoriatic Arthritis&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;General Considerations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 172&lt;/strong&gt;&lt;/span&gt;. Beginning with the first visit, the patient with PsA should be evaluated, at a minimum, for disease activity, function, and structural damage, as well as treatment response and toxicity, and prognosis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;First Evaluation of the Patient with PsA or Suspected PsA&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 173&lt;/strong&gt;&lt;/span&gt;. The first evaluation of a patient with PsA/suspected PsA should include: medical history, physical examination, laboratory tests (at a minimum: complete blood count, chemistry panel, ESR, CRP, RF), radiographic study (chest, sacroiliac joints, other affected joints) and assessment of prognosis &lt;strong&gt;[5, D]&lt;/strong&gt;. (See Table 78 in the original guideline document for more information on the first evaluation of the patient with PsA.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 174&lt;/strong&gt;&lt;/span&gt;. In evaluating the different domains of PsA it is important to take into account the contribution of both musculoskeletal and other manifestations of the disease, like skin involvement &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 175&lt;/span&gt;&lt;/strong&gt;. In patients with PsA, pain should be evaluated and the PtGA and PhGA should be obtained with reference to the past week (preferably using horizontal numerical scales from 0 to 10, or alternatively the visual analog scale [VAS] from 0 to 10 cm) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 176&lt;/strong&gt;&lt;/span&gt;. Fatigue should be evaluated, however, no specific instrument is recommended for this purpose. A horizontal numerical scale (1-10) would be acceptable &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 177&lt;/strong&gt;&lt;/span&gt;. The evaluation of PsA patients should include a peripheral joint assessment (66 joints for swelling and 68 joints for tenderness) &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 178&lt;/strong&gt;&lt;/span&gt;. Axial involvement in PsA should be evaluated with the BASFI, modified Sch&amp;ouml;ber test, lateral flexion of the lumbar spine, finger-floor distance, chest expansion, occiput-wall/tragus-wall distance, and cervical rotation &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 179&lt;/strong&gt;&lt;/span&gt;. No particular enthesitis index is recommended in PsA patients, but the MASES index appears to be preferable &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 180&lt;/strong&gt;&lt;/span&gt;. Patients with PsA should be evaluated routinely for dactylitis, indicating its presence/absence and whether it is acute or chronic &lt;strong&gt;[1b, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 181&lt;/strong&gt;&lt;/span&gt;. The quality of life of these patients should be evaluated using the SF-12 or SF-36 &lt;strong&gt;[1b, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 182&lt;/strong&gt;&lt;/span&gt;. The Health Assessment Questionnaire (HAQ) is recommended for the evaluation of function (disability) in PsA patients with peripheral joint involvement &lt;strong&gt;[1b, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 183&lt;/strong&gt;&lt;/span&gt;. No particular instrument is recommended for the assessment of skin and nail involvement in daily practice, but clinicians should note the presence or absence of onychopathy, and a dermatologist should be consulted in case of doubt &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 184&lt;/strong&gt;&lt;/span&gt;. In patients with suspected PsA, radiographs should be obtained of the affected skeletal regions as well as an AP radiograph of the pelvis to detect sacroiliitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 185&lt;/strong&gt;&lt;/span&gt;. No particular method for the assessment of structural damage is recommended; the Sharp-van der Heijde index modified for PsA is preferable for peripheral joint assessment, and the Modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) for axial involvement &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 186&lt;/strong&gt;&lt;/span&gt;. Both ESR and CRP should be evaluated in PsA &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 187&lt;/strong&gt;&lt;/span&gt;. PsA prognosis should be assessed taking into account factors such as sex, number of swollen joints, ESR, drug failure, and disease with joint damage, loss of function, or reduced quality of life &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Assessment During Follow-up of PsA&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 188&lt;/strong&gt;&lt;/span&gt;. Systematic follow-up of PsA patients should include collection of socio-occupational, clinical, analytic, and radiological data, as well as treatment response/toxicity. The frequency of follow-up will depend on the type of variable and patient characteristics &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Frequency of Follow-up&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 189&lt;/strong&gt;&lt;/span&gt;. Patients with PsA should be followed up at least once a year if they are controlled and do not require other pharmacological monitoring &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 190&lt;/strong&gt;&lt;/span&gt;. Patients with PsA who need to be evaluated for treatment effectiveness or therapeutic compliance, or whose drugs require specific monitoring, should be assessed every 2 weeks to 3-4 months &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 191&lt;/strong&gt;&lt;/span&gt;. Patients with PsA and severe exacerbation, unexpected adverse effects to treatment, fever, or rapid deterioration of their general condition should be evaluated in the shortest possible time, no later than one week &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Evaluation of Treatment Response&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 192&lt;/strong&gt;&lt;/span&gt;. The definitions listed below are recommended &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Remission&lt;/strong&gt; of disease is defined as the absence of signs, symptoms, and any other findings indicative of PsA activity.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Active disease&lt;/strong&gt; is defined as:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In oligoarticular forms, if there is persistence of arthritis/enthesitis and PtGA &amp;gt;4 or acute phase reactants are elevated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In polyarticular forms, if DAS28 &amp;ge;2 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In cases of axial involvement, if BASDAI &amp;gt;4 and at least one of: PtGA &amp;gt;4, nocturnal axial pain &amp;gt;4 or elevated acute phase reactants &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment Response Measures/Criteria&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 193&lt;/strong&gt;&lt;/span&gt;. In assessing the response to treatment the use of a composite index is recommended, such as the DAS28 (preferable, and using a count of 66 swollen joints and 68 tender joints), the Psoriatic Arthritis Response Criteria (PsARC), or the American College of Rheumatology (ACR) response criteria modified for PsA &lt;strong&gt;[5, D]&lt;/strong&gt;. (See Tables 81 and 82 in the original guideline document for more information on psoriatic arthritis response criteria.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 194&lt;/span&gt;&lt;/strong&gt;. The recommended variables for treatment response in PsA are the DAS28, BASDAI, PtGA, nocturnal back pain, and the acute phase reactants &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Changes in Treatment&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 195&lt;/span&gt;&lt;/strong&gt;. Whenever the therapeutic goal is not achieved in PsA, a treatment decision must be made &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 196&lt;/strong&gt;&lt;/span&gt;. PsA patients who reach the treatment goal should continue the prescribed treatment at the minimum effective dose &lt;strong&gt;[5, D]&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 197&lt;/strong&gt;&lt;/span&gt;. Patients with peripheral PsA should be considered as not responding to treatment if arthritis/enthesitis persists after 3-4 months of treatment at full/maximum tolerated doses of (NSAIDs and DMARDs, local GCs and synovectomy), and PtGA &amp;ge;4 and/or acute phase reactants are elevated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 198&lt;/strong&gt;&lt;/span&gt;. Patients with axial PsA should be considered as not responding to treatment if, after 3-4 months of treatment at full/maximum tolerated doses of at least two NSAIDs, the BASDAI is &amp;ge;4 and (one of the following): PtGA &amp;ge;4, nocturnal pain &amp;ge;4 and/or acute phase reactants are elevated &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 199&lt;/strong&gt;&lt;/span&gt;. The response to an anti-TNF-&amp;alpha; agent should be evaluated in PsA every 3-4 months, taking into account the DAS28, BASDAI, PtGA, nocturnal back pain, and acute phase reactants &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;General Considerations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 200&lt;/strong&gt;&lt;/span&gt;. The choice of treatment in PsA should be based on disease and patient characteristics &lt;strong&gt;[5, D]&lt;/strong&gt;. (See Table 83 in the original guideline document for the factors on which to base treatment in patients with PsA.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pharmacological Treatment of Psoriatic Arthritis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;NSAIDs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 201&lt;/span&gt;&lt;/strong&gt;. The use of NSAIDs is recommended to control symptoms in patients with PsA and peripheral arthritis &lt;strong&gt;[1b, A]&lt;/strong&gt;, as well as for axial involvement &lt;strong&gt;[1b, A]&lt;/strong&gt;, enthesitis &lt;strong&gt;[4, D]&lt;/strong&gt;, and dactylitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;GCs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 202&lt;/strong&gt;&lt;/span&gt;. In patients with PsA, the use of systemic GCs is recommended in very selected cases of severe joint involvement &lt;strong&gt;[5, D]&lt;/strong&gt;. GC infiltrations are recommended in patients with monoarthritis, oligoarthritis, or polyarthritis with one or two especially symptomatic joints &lt;strong&gt;[5, D]&lt;/strong&gt;, and in enthesitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;DMARDs&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 203&lt;/span&gt;&lt;/strong&gt;. The use of SSZ in PsA is recommended for the treatment of arthritis &lt;strong&gt;[1a, A]&lt;/strong&gt; and dactylitis &lt;strong&gt;[2a, B]&lt;/strong&gt;, but not for enthesitis &lt;strong&gt;[1a, A]&lt;/strong&gt; or axial involvement &lt;strong&gt;[1c, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 204&lt;/strong&gt;&lt;/span&gt;. The use of MTX is recommended in PsA patients with peripheral arthritis &lt;strong&gt;[2a, B]&lt;/strong&gt;, refractory enthesitis &lt;strong&gt;[5, D]&lt;/strong&gt; and dactylitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 205&lt;/strong&gt;&lt;/span&gt;. The use of LEF should be evaluated in PsA with peripheral arthritis and dactylitis &lt;strong&gt;[1b, A]&lt;/strong&gt;, and may be considered in cases of refractory enthesitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 206&lt;/strong&gt;&lt;/span&gt;. The use of CsA should be evaluated in PsA for the treatment of arthritis and dactylitis &lt;strong&gt;[2b, B]&lt;/strong&gt;, and may be considered in cases of refractory enthesitis &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 207&lt;/strong&gt;&lt;/span&gt;. The use of AZA, gold salts, D-penicillamine, and antimalarials should be evaluated in patients with clinically active PsA provided that other treatments have failed or are not possible, and the potential benefit is considered to outweigh the possible adverse effects &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment with Anti-TNF-&amp;alpha; Agents&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 208&lt;/strong&gt;&lt;/span&gt;. When the use of an anti-TNF-&amp;alpha; is indicated, the choice of agent will depend on the physician's judgment and on each patient's particular manifestations and circumstances &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 209&lt;/strong&gt;&lt;/span&gt;. The use of IFX is recommended in patients with peripheral PsA who are refractory to NSAIDs, DMARDs and symptomatic treatments (analgesics, local GC infiltrations, synoviorthesis), and in PsA patients with axial disease who are refractory to NSAIDs and other symptomatic treatments (analgesics, local GC infiltrations) &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 210&lt;/strong&gt;&lt;/span&gt;. The use of ETN is recommended in patients with peripheral PsA who are refractory to NSAIDs, DMARDs and symptomatic treatments (analgesics, local GC infiltrations, synoviorthesis), and in PsA patients with axial disease who are refractory to NSAIDs and other symptomatic treatments (analgesics, local GC infiltrations) &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 211&lt;/strong&gt;&lt;/span&gt;. The use of ADA is recommended in patients with peripheral PsA who are refractory to NSAIDs, DMARDs and symptomatic treatments (analgesics, local GC infiltrations, synoviorthesis), and in PsA patients with axial disease who are refractory to NSAIDs and other symptomatic treatments (analgesics, local GC infiltrations) &lt;strong&gt;[1a, A]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Other Pharmacological Treatments&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Recommendation 212&lt;/span&gt;&lt;/strong&gt;. Infiltration with slow release GCs is recommended in patients with PsA &lt;strong&gt;[4, C]&lt;/strong&gt;, taking care to avoid areas of psoriasis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 213&lt;/strong&gt;&lt;/span&gt;. In patients who are refractory to conventional treatments including GC infiltration, radioisotope synovectomy should be evaluated (administered together with GCs) if the arthritis is highly symptomatic and/or causes major functional impairment &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Non-Pharmacological Treatment of PsA&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Education&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 214&lt;/strong&gt;&lt;/span&gt;. PsA patients should be informed about all aspects related to their disease, including its course and complete information about its treatment &lt;strong&gt;[4, C]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Rehabilitation&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 215&lt;/strong&gt;&lt;/span&gt;. In PsA the type, technique, or program of exercise should be adjusted to the specific requirements of the patient's disease, characteristics, particular circumstances and preferences, as well as the available resources &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 216&lt;/strong&gt;&lt;/span&gt;. Routine physical exercise should be recommended for all PsA patients &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 217&lt;/strong&gt;&lt;/span&gt;. Patients with PsA should use all available strategies to increase the level of compliance with the exercise program, especially in the case of exercises done at home &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Surgical Treatment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 218&lt;/strong&gt;&lt;/span&gt;. Surgical treatment should be recommended in PsA patients with important pain and/or disability refractory to medical treatment &lt;strong&gt;[2b, B]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Patients and Nurses in SpA&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Role of Patients and Patient Associations in SpA&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;General Considerations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 219&lt;/strong&gt;&lt;/span&gt;. The most active possible participation of the patient in all disease-related processes is recommended, including research &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Patient Associations&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 220&lt;/strong&gt;&lt;/span&gt;. Patients should be given more information on all aspects related to their disease at the beginning of the disease process and throughout its entire course &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 221&lt;/strong&gt;&lt;/span&gt;. Knowledge, awareness, and dissemination of the work of patient associations should be increased, and explicit information should be provided to all patients on the possibilities offered by these associations &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The Role of Nurses in SpA&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recommendation 222&lt;/strong&gt;&lt;/span&gt;. The rheumatological care of patients with SpA should include care provided by nursing staff &lt;strong&gt;[5, D]&lt;/strong&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 2, &quot;Levels of Evidence of the Oxford Center of Evidence-Based Medicine,&quot; and the accompanying explanatory notes in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Table 2, &quot;Levels of Evidence of the Oxford Center of Evidence-Based Medicine,&quot; and the accompanying explanatory notes in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The original guideline document contains the following clinical algorithms:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Decision tree for the diagnosis of axial spondyloarthritis (SpA) (and its probabilities) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Changes in the treatment of axial forms of ankylosing spondylitis and psoriatic arthritis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Changes in the treatment of peripheral ankylosing spondylitis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Changes in the treatment of peripheral psoriatic arthritis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Algorithm for evaluation of anti-tumor necrosis factor alpha (anti-TNF &amp;alpha;) in axial involvement &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring anti-TNF&amp;alpha; in polyarticular forms of arthritis. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of spondyloarthritis (SPA)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;See Tables 37-49 in the original guideline document for a summary of adverse effects of pharmacologic treatments. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;See the sections on treatment of spondyloarthritis (SpA), ankylosing spondylosis (AS), and psoriatic spondyloarthritis (PsA) in the original guideline document for additional details on adverse effects of treatments. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Contraindications to Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Severe liver failure&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Contraindications to Use of Disease-Modifying Antirheumatic Drugs (DMARDS), Pamidronate, Thalidomide, and Biological Agents&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See Tables 40, 43, 45, and 46 in the original guideline document for contraindications to disease-modifying antirheumatic drugs (DMARDS), pamidronate, thalidomide, and biological agents.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Contraindication to Cervical Traction&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Surgery on the temporomandibular joint&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Contraindications to Spinal Manipulations (Absolute)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Spinal manipulations are absolutely contraindicated in patients with advanced AS who have active inflammation and/or stiff or inflexible spines and/or fragile or unstable spines, especially if they are middle aged or elderly.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers have tried to make the recommendations clear and practical. But they also sought flexibility, a necessary characteristic if the clinical practice guideline (GPC) is to be applicable in the real world, where different circumstances (availability of particular technologies, training, patients' personal preferences, etc.), may affect clinical decision making; thus, at times the choice among various possibilities which the panel deemed to be equally valid is left to the judgment of the user of the GPC.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Espoguia Group. Espoguia. Clinical guidelines for patients with spondyloarthritis. Madrid: Spanish Society of Rheumatology; 2010. 289 p.  [1104 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Spanish Society of Rheumatology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This clinical practice guideline (GPC), sponsored by the Spanish Society of Rheumatology (SER), was financed by Abbott. The contract signed between the Spanish Foundation of Rheumatology (Spanish acronym, FER), the organization that employs the staff of the SER Research Unit and coordinated payments to the panelists and reviewers as the only intermediary, and the pharmaceutical laboratory, established total independence from the laboratory participants, who could not influence its contents; the contract also established that the laboratory committed to financing the GPC, even in the event that the evidence argued against indication of any of its products.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Spanish Society of Rheumatology (SER) Working Group for the Study of Spondyloarthropathies&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Coordinators&lt;/em&gt;: Loreto Carmona, Rheumatologist and epidemiologist, Director of the SER Research Unit; Est&amp;iacute;baliz Loza, Rheumatologist and investigator in the SER Research Unit; Juan Antonio Mart&amp;iacute;nez L&amp;oacute;pez, Rheumatologist in post-MIR training, Hospital de la Princesa and SER Research Unit.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Panelists&lt;/em&gt;: Raquel Almod&amp;oacute;var Gonz&amp;aacute;lez, Rheumatology, Fundaci&amp;oacute;n Hospital Alcorc&amp;oacute;n, Madrid; Manuel Arias; Enrique Batlle Gualda, Rheumatology, Hospital Universitario de Alicante, Alicante; Pedro Carpintero Ben&amp;iacute;tez, Traumatology and Orthopedic Surgery, Hospital Universitario Reina Sof&amp;iacute;a, C&amp;oacute;rdoba; Eduardo Collantes Est&amp;eacute;vez, Rheumatology, Hospital Reina Sof&amp;iacute;a, C&amp;oacute;rdoba; David D&amp;iacute;az Valle, Ophthalmology, Hospital Cl&amp;iacute;nico San Carlos, Madrid; Alejandro Escudero Contreras, Rheumatology, Hospital Universitario Reina Sof&amp;iacute;a, C&amp;oacute;rdoba; Mariano Tom&amp;aacute;s Fl&amp;oacute;rez Garc&amp;iacute;a, Physical Medicine and Rehabilitation, Hospital Universitario Fundaci&amp;oacute;n Alcorc&amp;oacute;n, Madrid; Fernando Garc&amp;iacute;a P&amp;eacute;rez, Hospital Universitario Fundaci&amp;oacute;n Alcorc&amp;oacute;n, Madrid; Juan Luis Garrido Castro, Asociaci&amp;oacute;n Cordobesa de Enfermos Afectados de Espondilitis (ACEADE), C&amp;oacute;rdoba; Ana Guti&amp;eacute;rrez Casbas, Specialist in Gastroenterology, Hospital General Universitario de Elche; Luis Francisco Linares Ferrando, Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia; Ram&amp;oacute;n Mazzucchelli Esteban, Rheumatology, Hospital Universitario Fundaci&amp;oacute;n Alcorc&amp;oacute;n, Madrid; Manuel Jos&amp;eacute; Moreno Ramos, Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia; Juan Mulero Mendoza, Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid; Laura Mu&amp;ntilde;oz; Mar&amp;iacute;a Carmen Mu&amp;ntilde;oz Villanueva, Senior Research Technician, Hospital Universitario Reina Sof&amp;iacute;a, C&amp;oacute;rdoba; Ver&amp;oacute;nica P&amp;eacute;rez Guijo; Rub&amp;eacute;n Queiro Silva, Rheumatology, Hospital Universitario Central de Asturias (HUCA), Oviedo; Francisco Javier Quir&amp;oacute;s Donate, Rheumatology, Hospital Universitario Fundaci&amp;oacute;n Alcorc&amp;oacute;n, Madrid; Diana P. Ruiz Genao, Dermatologist, Hospital Universitario Fundaci&amp;oacute;n Alcorc&amp;oacute;n, Madrid; Alejandro Tejedor Varillas, Specialist in Family and Community Medicine, CS Las Ciudades &amp;Aacute;rea X SERMAS, Madrid; Juan Carlos Torre Alonso, Rheumatology, Hospital Universitario Fundaci&amp;oacute;n Alcorc&amp;oacute;n, Madrid&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Reviewers&lt;/em&gt;: Miguel &amp;Aacute;ngel Abad Hern&amp;aacute;ndez, Rheumatology, Hospital Virgen del Puerto de Plasencia, C&amp;aacute;ceres; Cayetano Alegre de Miquel, Rheumatology, Hospital Universitario Valle de Hebr&amp;oacute;n and Instituto Universitario Dexeus, Barcelona; Tatiana Cobo Ib&amp;aacute;&amp;ntilde;ez, Rheumatology, Hospital Infanta Sof&amp;iacute;a, Madrid; Jos&amp;eacute; De La Mata Llord, Rheumatology, Cl&amp;iacute;nica del Valle, Madrid; M&amp;ordf; Rosa Gonz&amp;aacute;lez Crespo, Rheumatology, Hospital Doce de Octubre, Madrid; Jes&amp;uacute;s Maese Manzano, Rheumatology, Madrid; Betina Nishishinya, Rheumatology, Hospital Asil de Granollers, Barcelona; Ana Ortiz Garc&amp;iacute;a, Rheumatology, Hospital Universitario de la Princesa, Madrid; Claudia Alejandra Pereda Testa, Rheumatologist, Cl&amp;iacute;nica Mediterr&amp;aacute;neo, Almer&amp;iacute;a&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All panelists were requested to guarantee their availability during the time in which ESPOGUIA was to be developed, and to provide a curriculum vitae and a document stating their conflicts of interest. No participant was excluded due to conflicts of interest. Panelists received compensation in the form of an allowance for each meeting they attended and after completing their corresponding chapter.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is planned to update ESPOGUIA about every 2 years.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in &lt;a href=&quot;http://www.ser.es/practicaClinica/espoguia/anexos/Espoguia-ENG.pdf&quot; title=&quot;Spanish Society of Rheumatology Web site&quot;&gt;English&lt;/a&gt; and &lt;a href=&quot;http://www.ser.es/ArchivosDESCARGABLES/Proyectos/Espoguia/EspoguiaESP.pdf&quot; title=&quot;Spanish Society of Rheumatology Web site&quot;&gt;Spanish&lt;/a&gt; from the Spanish Society of Rheumatology Web site.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies (Spanish): Available from the Spanish Society of Rheumatology. C/Marqu&amp;eacute;s del Duero, 5 - 1st floor, 28001 Madrid, Spain; Telephone: +34 91 5767799; Fax: +34 91 5781133; e-mail: ser@ser.es.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Quick reference guide (Spanish). Madrid: Spanish Society of Rheumatology; 2010. 39 p. Electronic copies: Available from the &lt;a href=&quot;http://www.ser.es/practicaClinica/espoguia/anexos/Guia_rapida_Espoguia.pdf&quot; title=&quot;Spanish Society of Rheumatology Web site&quot;&gt;Spanish Society of Rheumatology Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies (Spanish): Available from the Spanish Society of Rheumatology. C/Marqu&amp;eacute;s del Duero, 5 - 1st floor, 28001 Madrid, Spain; Telephone: +34 91 5767799; Fax: +34 91 5781133; e-mail: &lt;a href=&quot;mailto:ser@ser.es&quot;&gt;ser@ser.es&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition, various charts and checklists for diagnostic or referral criteria are available in the &lt;a href=&quot;http://www.ser.es/practicaClinica/espoguia/anexos/Espoguia-ENG.pdf&quot; title=&quot;Spanish Society of Rheumatology Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on October 24, 2011. The information was verified by the guideline developer on November 2, 2011. This summary was updated by ECRI Institute on October 28, 2013 following the U.S. Food and Drug Administration advisory on Acetaminophen. This summary was updated by ECRI Institute on September 18, 2015 following the U.S. Food and Drug Administration advisory on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the Spanish Society of Rheumatology's copyright restrictions. The contents of this Clinical Practice Guideline may be used and reproduced without special permission so long as the source is credited.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
